Gastroenterology Research and Practice / 2020 / Article / Tab 1

Research Article

Impact of Hepatic Steatosis on the Antiviral Effects of PEG-IFNα-2a in Patients with Chronic Hepatitis B and the Associated Mechanism

Table 1

Baseline characteristics of 226 chronic hepatitis B patients.

VariableDegrees of hepatic steatosis value value
S0 ()S1 ()S2 ()S3 ()

Male ( (%))82 (68.91%)65 (85.53%)21 (95.46%)9 (100%)14.8280.002
Age2.0630.106
Age >40 ( (%))6 (5.04%)15 (19.74%)1 (4.55%)0 (0%)13.280.004
Course of disease0.3270.806
TC5.7030.001
TG13.1800.001
UA4.2710.006
Hyperuricaemia ( (%))18 (15.13%)17 (22.37%)9 (40.91%)6 (66.67%)18.2550.001
Metabolic syndrome ( (%))1 (0.84%)3 (3.95%)1 (4.55%)1 (11.11%)4.5372.063
GLU9.4040.001
ALT4.3470.005
AST7.5600.001
HBVlog10 (IU/mL) DNA1.2240.302
HBsAg (log IU/mL)1.2730.283
HBV genotype1.000.616
B35 (29.41%)23 (30.26%)7 (31.83%)3 (33.33%)
C78(65.55%)50 (65.79%)14(63.64%)6 (66.67%)
Mix6(5.04%)3 (3.95%)1 (4.55%)0
BMI36.9960.001
14 (11.76%)54 (71.05%)14 (63.64%)7 (77.77%)80.9320.001

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.